Verrica Pharmaceuticals Enters Material Definitive Agreement
Ticker: VRCA · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, contract
TL;DR
Verrica Pharma signed a big deal, details TBD.
AI Summary
On June 26, 2024, Verrica Pharmaceuticals Inc. entered into a Material Definitive Agreement. The filing does not disclose the specific details of this agreement, only that it is a significant contract.
Why It Matters
This filing indicates a significant new contract for Verrica Pharmaceuticals, which could impact its future revenue and operations.
Risk Assessment
Risk Level: medium — The lack of specific details about the Material Definitive Agreement introduces uncertainty regarding its terms and potential impact.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Verrica Pharmaceuticals?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on June 26, 2024.
What is the effective date of the Material Definitive Agreement?
The earliest event reported, which is the entry into the Material Definitive Agreement, occurred on June 26, 2024.
Does this 8-K filing provide any financial details related to the agreement?
No, this filing does not provide any specific financial details or dollar amounts related to the Material Definitive Agreement.
Where is Verrica Pharmaceuticals Inc. headquartered?
Verrica Pharmaceuticals Inc. is headquartered in West Chester, PA.
What is the standard industrial classification for Verrica Pharmaceuticals Inc.?
The standard industrial classification for Verrica Pharmaceuticals Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-06-28 16:17:03
Key Financial Figures
- $500,000 — to pay the lenders an amendment fee of $500,000. Except as set forth in the Amendment
Filing Documents
- d844833d8k.htm (8-K) — 23KB
- 0001193125-24-172277.txt ( ) — 142KB
- vrca-20240626.xsd (EX-101.SCH) — 3KB
- vrca-20240626_lab.xml (EX-101.LAB) — 18KB
- vrca-20240626_pre.xml (EX-101.PRE) — 11KB
- d844833d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: June 28, 2024 /s/ P. Terence Kohler, Jr. P. Terence Kohler, Jr. Chief Financial Officer